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Abstract
Pin1 is an enzyme essential to cell cycle regulation and has a key role in
cancer proliferation. This thesis reports ongoing efforts to obtain a Pin1 inhibitor
exhibiting an inhibition constant in the nanomolar range.
It was previously found that Pin 1 activity could be inhibited using a short
proline containing peptide sequence which also contains a stereospecific (3substituted a-amino acid. Several proline analogues were tested for greater
inhibition against Pin1 than previously synthesized Cbz-/_-Glu((3-phos)-Pro-NH2.
It was found that using full length Pin1 in the chymotrypsin-coupled photometric
assay rendered different values than using only the catalytic PPIase domain for
Cbz-Z_-Glu((3-phos)-Pro-NH2, Kj = 54.1+1.8 pM and 20 ± 0.9 pM respectively.
The potential effectiveness of the synthesized inhibitors against Pin1 was
assessed using the same convenient chymotrypsin-coupled photometric assay
against full length Pin1.
This thesis describes the synthesis of two novel compounds which
exhibited an increase in inhibition relative to Cbz-/_-Glu((3-phos)-Pro-NH2 (Kj =
54.1+1.8 pM) with results in the micromolar range; Cbz-Z_-Glu(f3-phos)-Pip-NH2
(Kj = 45.4+1.1 pM) and Cbz-/_-Glu(p-phos)-Methylpiperazine (Kj = 22.7+1.4 pM).

Keywords: Pin1, OBO ester, Pin 1 inhibition, ß-substituted glutamic acid,
Chymotrypsin coupled kinetic assay.
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Chapter One: Introduction

1.1

Peptidyl-Prolyl cis-trans Isomerase (PPIase) Activity
Proteins are a sequence of amino acids linked together in series through

amide or peptide, bonds. Due to the partial double bond properties in the amide
bond there are two conformations available in each peptide bond called cis and
trans. Cis and trans can be defined as the dihedral angle, oo, between
neighbouring a-carbons with an angle of 180° for trans and 0° for cis (see Figure
1.1). The trans conformation of a peptide bond is favoured over the cis
conformation in nearly all naturally occurring peptide bonds. This is due to
increased conformational strain experienced in the cis conformation through
steric hindrance. The steric hindrance experienced is between neighbouring acarbon substituents, both the residue side chain as well as the carbonyl group.
However, in a proline containing peptide bond, where proline is on the nitrogen
side of the bond, both the cis and trans conformations are closer in terms of
steric hindrance due to the higher substitution on the amide nitrogen (Figure 1.1).
With the higher substitution on the nitrogen, the propensity for the trans isomer is
reduced from 1000:1, in a non-proline containing peptide bond, to approximately
3:1, with proline on the nitrogen side of the peptide bond. Thus, both isomers are
naturally found in biological conditions.
Peptidyl-prolyl

cis-trans

isomerase

(PPIase)

activity

catalyzes

the

relatively slow cis-trans isomerization of the prolyl-amide bond. PPIase activity
affects protein regulation, folding, and biological activity of many target proteins

l

[1-4]. PPIase activity is ubiquitously found in both prokaryotic and eukaryotic
organisms. There are three families of proteins which posses PPIase activity; the
FK506 binding proteins (FKBPs), the cyclophilins (CyPs), and the parvulin family
of proteins.

Figure 1.1 Visual representation of A) non-proline containing peptide bond in trans and
cis conform ations and B) proline containing peptide bond in trans and cis conformations.

The CyPs and FKBPs, which are also known as immunophilins, possess
immunosuppressant activity [5] and bind to the immunosuppressant drugs
cyclosporin A (CsA) and FK506 respectively, from which they derive their names
[6], However, the PPIase functionality of the immunophilins is not necessary for
their immunosuppressive effects. It is the topology of the protein-drug complex
which affects immunosuppressant activity. Upon binding to the respective
immunosuppressant drug, the topology of the protein changes which then
interferes with the transduction pathway blocking T-cell activation [2, 6]. CyPs
and FKBPs have been shown to influence the folding of several proteins such as
2

collagen [7-9], carbonic anhydrase [10, 11], chymotrypsin inhibitor [12], and
ribonuclease [13]. However, there is no definitive evidence that the PPIase
activity of both the CyPs and FKBPs is essential in vivo.
PPiC (peptidyl-prolyl cis-trans isomerase), isolated from E. coli, was the
first of the parvulin family to be categorized [14, 15]. The human homologue Pin1,
Peptidylprolyl cis/trans Isomerase, NIMA-interacting 1, was later discovered
through a yeast two-hybrid screen designed to locate proteins which interact with
Never in Mitosis Gene A (NIMA) [16].

1.2

Pin1
The enzyme Pin1 has been implicated in cell cycle control [17, 18],

cytokine production [19-21], neurodegenerative disorders [22, 23], Human
Immunodeficiency Virus (HIV) proliferation [24], and tumourgenesis [25] making it
an attractive target for research.

1.2.1

Structure, Domains, and Recognition Motif of Pin1
Whereas Pin4/Par14 found in mice, consists only of a PPIase domain,

Human Pin 1 is composed of two domains, the tryptophan rich WW domain on
the N-terminus (residues 1-39) and the C-terminal catalytic PPIase domain
(residues 45-163) [16, 26],
The WW domain binds to proline rich or proline containing regions of
proteins/peptides [27]. The WW domain of Pin 1 is classified as a Group IV
protein-protein interaction domain which binds to pSer/pThr proline ligands [27].

3

The small domain is an anti-parallel (3-sheet consisting of three strands
connected in series with short loop regions. Interestingly, the WW domain family
is the smallest protein domain classified that does not require any ligands,
disulphide bonds, or cofactors to remain stable [28], Furthermore, the WW
domain has been shown to act as a recruiting domain, allowing interaction
partners to bind as well as bring substrates close to enzymes [29].
The

larger

PPIase

domain

also

interacts

with

proline

containing

sequences, specifically with ligands containing pSer/pThr-proline. The PPIase
domain consists of a (3-sheet of four strands arranged in an anti-parallel fashion
forming a beta roll in the center of the domain, one 3/10 helix, and three ahelices. Helices 1-3 (a-helix 1 and 2 as well as the 3/10 helix) are arranged
around the central sheet on the convex side of the roll. However, helix 4 (a-helix
3) is arranged on the concave side of the roll effectively closing the gap one on
side of the roll. The active site on the domain is located on the open side of the
roll. The PPIase domain is highly conserved in the parvulin family among most
species [30].
Currently

there

is

conflicting

evidence

on

the

overall

structural

arrangement of the protein domains. NMR data suggests that the WW domain
and the PPIase domain remain loosely arranged, whereas crystal structure data
promotes close interaction between the WW and PPIase domains [31, 32].
Figure 1.2 depicts both NMR and crystal structures of Pin1.

4

A)

Figure 1.2 The PPIase dom ain, denoted by hollow arrows, are in approxim ately the
sam e orientation to dem onstrate the high degree of freedom of m ovem ent of the W W
dom ain, denoted by solid arrows. A) Crystal structure, pdb code 2ZQS, of Pin1 mutant
C113A [31] B) NMR structure, pdb code 1NMV, of Pin1 [32].

1.2.2 Pin1 PPIase Mechanism
The mechanism of Pin1 activity is not fully understood, however, it is
known that Pin1 does not make or break a bond [33]. The rotation of solely the
prolyl-amide bond, while maintaining the conformation of all other bonds, is
considered a highly unfavourable mechanism. For the rotation of only the prolylamide bond a large shift in the ligand’s structure would have to occur. This would
require a large amount of free energy in the transition state. This mechanism of
action may be possible for smaller peptide structures; however, this could lead to
an unfavourable loss of binding energy in the complex. The rotation of the prolyl
5

peptide bond could also be accomplished by the rotation of several other
adjacent bonds to

achieve

an overall

pSer/pThr-Pro

isomerization

[34].

Furthermore, it is possible that the rotation of other bonds could be “pre
determined” in target proteins and act in the signaling mechanism of the target
protein [34].

1.2.3 Pin1 Interaction Partners and Disease States
The action of Pin 1 ultimately alters the stability, functionality, and/or final
cellular location of the target molecules. This has a downstream effect in the
biological pathways the target molecules belong to [4]. To name a few,
interactions

with

NIMA

[16],

Cyclin

D1

[18],

Cdc25

phosphatase

[35],

phosphorylated Myt1 [35], PLK1 [36], p73 [37], p53 [38], phosphorylated tau
protein [39, 40], and CK2 [41] have been identified for Pin 1. All of these Pin1
interactions occur in a phosporylation dependant manner [4, 40, 42], Pin1 has
also been shown to interact with transcription factors such as RNA Polymerase II
(RNAP2) [4]. Clearly, Pin1 has an important role in cell regulation and function.

1.3

Pin1 in Cell Cycle Regulation and Cancer
NIMA is a mitotic kinase in Asperillus nidulans where overexpression

induces premature chromosome condensation followed by apoptosis. However, if
Pin 1 is also overexpressed there is a prevention of the premature chromosome
condensation. It was also shown that the overexpression of just Pin1 leads to the
inhibition of transition into mitosis causing G2 arrest [16], In this case G2 arrest is

6

caused by the inactivation of cell division cycle 2 (CDC2) and Cyclin B [42], Low
Pin 1 levels have been shown to cause an increase in abnormal G2 to M
transitions [17]. In this regard, Pin1 could potentially act as a molecular timer for
the cell cycle.
However, Pin1 has been found to be up-regulated in several cancers
including prostate, ovarian, and breast [43]. It is possible that up-regulation or
overexpression of Pin 1 can lead to uncontrolled abhorrent cell proliferation
causing cancer.
Thus, there is evidence that Pin1 acts as a protector against oncogenic
transformations, as well as has a tumourigenic effect. It is clear that Pin1 has a
complex involvement in cell cycle regulation.

1.4

Pin1 and Alzheimer’s Disease
Pin 1 has been shown to regulate the phosphorylated state of both Tau

and amyloid precursor protein (APP) through cis/trans isomerization [23, 40].
Loss of Pin 1 function has shown an age dependent relationship for Tau and
related pathologies in mice. It has also been revealed that neural tissue of
Alzheimer’s disease patients have a significantly lower amount of functional Pin1
[39]. In the absence of Pin1, A(342 is formed which leads to plaque formation
whereas in the presence of Pin1 the supposedly benign a-APP is formed [40].
Thus, it can be concluded that Pin 1 acts to guard neural tissue from plaque
formation.

7

Interestingly, it was shown through a longitudinal study that there is an
inverse correlation between Alzheimer’s disease and cancer in patients [44], The
development of one disease seems to inhibit the development of the other. Pin1
expression and activity has been implicated in these findings.

1.5

HIV
The

human

cytosine

deaminase

APOBEC3G

(A3G)

restricts

the

incorporation and replication of Human Immunodeficiency Virus (HIV) virions in
human cells [45], In vivo assays indicate that cells containing a reduced activity
Pin1 mutant and wild type A3G have stronger resistance to HIV. However, cells
with wild type Pin 1 and wild type A3G have a higher incorporation rate of HIV
[24]. Cells containing no A3G were found to have the highest infection rate. Thus,
it can be concluded that Pin 1 activity is influential in HIV infection rate. The study
also concluded that wild type Pin1 has a strong interaction with A3G, while the
W34A Pin1 mutant has minimal interaction with A3G, providing evidence that the
interaction is not non-specific.
Interestingly, HIV-1 contains the genetic code for an accessory protein, Vif,
which is thought to increase the phosphorylation at Ser16 on Pin1. Pin1 is not
overexpressed in Vif mediated phosporylation control but it would appear that the
activity of pSer16 Pin 1 has been increased [24]. The mechanism for the
increased phosphorylation state and the increased activity is currently not well
understood.

8

1.6

Pini Inhibition
As mentioned, Pin1 has an intricate and not fully understood role in

several different cellular functions. The ability for researchers to control the
function of Pin1 could lead to break-through developments in cancer, Alzheimer’s
disease, and potentially HIV research. Research into Pin1 inhibition began with
the discovery that juglone, 5-hydroxy-1,4-naphthalenedione, derived from the
black walnut (Juglans nigra) tree, was an irreversible inhibitor of Pin 1 [46].
Unfortunately, juglone has been shown to be too toxic, making it a poor
pharmaceutical agent [47],
The majority of the synthetic inhibitors for Pin1 are peptide sequences which
contain a proline analogue such as pipecolic acid (pip) [48-51] and/or other
hydrophobic, non-proteinaceous amino acids, such as naphthylalanine (NAL)
[50, 51] and 3-benzothienyl alanine (Bth) [50], many with Ki values in the nM-pM
range. These peptide chain style of inhibitors contain residues which are rnot part
of the recognition sequence of Pin1. The residues outside the binding picket are
free to interact with accessory binding pockets on the proteins surface near the
active site, thus increasing affinity. Table 1.1 demonstrates the sequences of a
select few peptide chain inhibitors.

9

Ac-Ala-Ala-(D)-Ser(P03H2)-Pro-Leu-pNA IC50 = 1.0 pM [52]
Ac-Ala-Ala-(D)-Ser(P03H2)-Pro-Arg-pNA IC50 = 3.6 pM [52]
Ac-Ala-Ala-(D)-Ser-Pro-Leu-pNA

IC50 = 85 pM [52]

cyclo(Arg-Arg-Arg-D-pThr-Pip-Nal-Arg-Arg-Gln) IC5o =1.1 pM [53]
cyclo(D-Ala-lle-D-pSer-Pro-Nal-Orn-Gln) IC50 = 1.1 pM [53]
cyclo(D-Arg-D-Arg-D-pThr-Pip-Nal-Arg-Gln) IC50 = 0.22 pM [53]
cyclo(Cys-Arg-Tyr-Pro-Glu-Val-Glu-lle-Cys) Kj = 0.5 pM [54]
Ac-Phe-D-Thr(P03H2)-Pip-Nal-Gln-NH2 Kj = 20.4 nM [51]
Ac-Bth-Thr(P03H2)-Pip-Nal-Gln-NH2 Ki = 258 nM [50]
Ac-Lys(A/-biotinoyl)-Ala-Ala-Phe-D-Thr(P03H2)-Pip-Nal-Gln-NH2 Kj = 4.8 nM [50]

Table 1.1 Peptide sequences of select peptide inhibitors.

Other compounds have also been designed as potential Pin1 inhibitors.
Different experimental approaches have been attempted such as testing different
ring structures [48], creating conformationally locked substrate mimics [55], and
synthesizing juglone-like molecules [56]. Figure 1.3 shows a selection of Pin1
inhibitors and their respective inhibition constants.

10

OH
HO— P= 0

0
K, = 18 [1M [48]

Kj = 0.8 |iM [49]

OH

I

H O -P -C

ii
0

A rg— NH2

Ac—Phe—Phe

IC50= 1.3 pM [55]

IC50 = 1.5 |iM [56]

Figure 1.3 Selection of Pin 1 inhibitors.

An attempt to increase the inhibiting potential of the dipeptide pSer-Pro
was explored previously by Laio and Lajoie (unpublished) through addition to the
serine

(3-carbon.

Laio

and

Lajoie

tested

the

effectiveness

of different

diastereomeric configurations of non-proteinaceous substitutions of ethyl, phenyl
and acetyl groups on the serine (3-carbon. The substitutions were then evaluated
for Pin1 inhibition. The addition of an acetyl group in the 2S, 3R configuration,
Cbz-Glu((3-phos)-Pro-NH2 (Figure 1.4), proved to have the best inhibiting ability
(Kj = 20.0+0.9 pM). From these studies it was postulated that the (3-carboxy
group binds to the arginine on the surface of Pin 1. This is based on modeling the
inhibitor with the crystal structure complex bound to a peptide inhibitor [51]. Using

li

the same crystal structure it was seen that there is potential for additional binding
in and around the proline binding pocket.

Figure 1.4 Structural representation of Cbz-G lu(p-phos)-Pro-N H 2

1.7

Stereoselective Synthesis of p-substituted Serine Analogues
A unique method for synthesis a of p-aldehyde serine analogue was

developed by Blaskovich and Lajoie in 1993 [57] and a full synthesis of CbzGlu(p-phos)-Pro-NH2 using the p-aldehyde strategy was completed by Laio and
Lajoie

in

2008

(unpublished).

The

method

utilizes

the

4-methyl-2,6,7-

trioxabicyclo[2.2.2]octane ester (OBO ester) to retain the functionality of the
carboxylic acid, to protect the chirality at the a-carbon as, well as to direct the
addition at the p-carbonyl. The orthoester is added to Cbz N-protected serine
through the esterification, and subsequent rearrangement, of oxetane to the
carboxylic acid. The OBO ester significantly reduces the acidity of the a-proton
which in turn reduces the propensity of enolization in the presence of the paldehyde, thus helping to maintain the chiral integrity of the a-carbon. The bulky
12

OBO ester also has the ability to direct stereoselective addition to the p-aldehyde
in

subsequent

reactions.

To

synthesize

Cbz-Glu(P-phos)-Pro-NH2,

the

Reformatsky addition was used to add a t-butyl protected acetate group to the 13carbon. The OBO ester was selectively removed and the resulting free acid was
coupled to proline using solid phase peptide synthesis and phosphorylated using
dibenzyl- N, N- diisopropylphosphoramidite. The full synthetic strategy used by
Laio and Lajoie (unpublished) is represented in Scheme 1.1.
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t-Bu

O

HO. Il -OH

98% TFA, 1% TIPS. 1%H,0

„Pro-NH,
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1.8

Stereoselective Addition to Carbonyl Groups
The process of addition to carbonyl groups to form enantiomerically

enriched compounds can be explained through three major models. Classically,
Cram’s rule [58] was applied in the formulation of stereospecific additions.
Cram’s rule states that the largest group on the (3-carbon to the aldehyde will
align parallel to the carbonyl if viewed using a Newman projection. This high
energy state was thought to stress the molecule thus increasing reactivity. The
prediction of the major product is such that the addition to the carbonyl will occur
with a higher frequency from the less hindered face, see Figure 1.5.

Major Product

Figure 1.5 M ajor product prediction using C ram ’s rule. W here L is a large substituent,
M is a m edium sized substituent and S is a small substituent such as hydrogen.

However, there was some experimental evidence that contradicted Cram’s
rule which lead to the development of the Felkin-Anh model [59]. The Felkin-Anh
model proposes that the largest R group on the carbon adjacent to the carbonyl
be perpendicular to the carbonyl a bond and parallel to the tr bond orbital. The
15

Burgi-Dunitz angle of attack would need to be satisfied for addition, and thus the
least hindered attacking angle is the preferred addition face (Figure 1.6).

Figure 1.6 Major product prediction using the Felkin-Anh model. W here L is a large
substituent, M is a m edium sized substituent and S is a small substituent such as
hydrogen.

An alternative way to predict the addition to a carbonyl group is through
chelation control. A soluble coordinating metal ion, such as Zn2+, is able to
coordinate with the carbonyl and adjacent functional groups which are electron
rich.

Depending on the existing configuration of the molecule the coordinating

ion will “hold” a target molecule in position to expose either the re or si face to the
nucleophile. The major product from 1, 2 or 1, 3 chelation control is completely

16

dependent on the existing stereochemistry, the existence of an electron donor
group, and the use of a coordinating metal ion (Figure 1.7)

Less hindered

More hindered

Figure 1.7 Major product prediction using 1, 2 chelation controlled addition. Where L is
a large substituent and S is a small substituent such as hydrogen.

The Felkin-Anh model and Cram’s rule do not always render the same
major product. The use of a less coordinating metal will reduce the effects of
chelation control in species which do poses electron rich centers. Using these
three models, chemical reactions can be optimized to produce a product in high
enantiomer excess.

1.9

Liquid Phase Peptide Synthesis
Liquid phase peptide synthesis (LPPS) is the original approach to peptide

synthesis. The growing peptide chain is assembled through a lengthy series of
coupling and purification steps. Some major drawbacks of LPPS are the difficult
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purification of the intermediate products and the length of time required for the
synthesis. A major development in peptide synthesis removed the difficult
purification by synthesizing peptide chains on insoluble resins.

1.10

Solid Phase Peptide Synthesis
Solid phase peptide synthesis (SPPS) was first developed in 1963 by

Robert Merrifield [60] and was a solution to the inconvenient purification between
coupling steps in LPPS. The growing peptide chain is linked via a chemical linker
to an insoluble solid support resin. The resin can be rinsed between coupling
steps, removing all unwanted elements of the synthesis, without the concern for
loss of product.

Synthesis of the peptide proceeds in the C-terminal to N-

terminal direction through the use of protected amino acids. There are two main
strategies available for SPPS: Boc and Fmoc. Both strategies use orthogonal
cleavage steps, where the N-terminus protecting group can be removed without
cleaving the resin-peptide linkage or the functional group protectors. In tbutyloxycarbonyl (Boc) chemistry the Boc N-protected residues are deprotected
by neat trifluoroacetic acid (TFA) and the side chain protecting groups and the
resin

linker/peptide

bond

can

be

cleaved

using

concentrated

HF.

9-

fluorenylmethyloxycarbonyl (Fmoc) is removed using 20% piperidine in DMF and
TFA removes the peptide from the resin and cleaves off the side chain protective
groups. Due to the use of extremely hazardous HF in the BOC strategy, Fmoc
chemistry is now generally preferred. Each residue addition cycle requires a
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deprotection of the N-protected group on the growing chain and addition of a Nprotected residue using hydroxybenzotriazole
yl)-1,1,3,3-tetramethyluronium

(HOBT), 2-(1 H-benzotriazole-1-

hexafluorophosphate

(HBTU)

and

diisopropylethylamine (DIPEA). The type of resin linker used determines the
properties of the cleaved product. For example, using PAL resin (5-(4-Fmocaminomethyl-3,5-dimethoxyphenoxy)-valeric acid-MBHA) as the solid support
leaves the peptide C-terminal end amidated upon cleavage, whereas using
Wang resin renders the C-terminal as a free carboxylic acid. Scheme 1.2
demonstrates a general synthesis of a dipeptide using an Fmoc protected PAL
resin.

Scheme 1.2

Q
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20% piperidine
in DMF
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----------------►
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20% piperidine
in DMF
---------------- ►

/-v-"--

{ j)

H

F m oc-aa2

aar NH2

---------- :--------►

O

aa2-Fmoc

H O B t /H B TU /D IPE A

1.11

Phosphorylation of Synthesized Peptides

In peptide synthesis there are two phosphorylation strategies available: 1)
using protected, phosphorylated amino acids as a building block during the
peptide synthesis and 2) the “global phosphorylation” method where all free
19

unprotected hydroxyls available are phosphorylated upon completion of the
peptide. Global phosphorylation requires the use of unprotected hydroxyl groups
on the residues which are intended to be phosphorylated. Global phosphorylation
is generally carried out using phosphoramidite class reagents such as Ndiisopropylphosphoramidite or N-dibenzoylphosphoramidite in the presence of
tetrazole to add phosphite ether to free hydroxyls. This is subsequently oxidized
to a phosophotriester using H2 O2 or mCPBA. The phosphate protecting groups
can then be removed using a strong acid such as TFA, which is convenient for
Fmoc SPPS as TFA will also cleave the protecting groups from other residues,
as well decouple the synthesized peptide from the solid support. Scheme 1.3
depicts a general global phosphorylation of a hydroxyl using dibenzyl- N, Ndiisopropylphosphoramidite.
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Scheme 1.3

1.12

Chymotrypsin Coupled Kinetic Assay

Inhibitors can be assayed using a convenient photometric assay developed
by

Fischer

et al.

[61],

see

Figure

1.8.

Chymotrypsin

hydrolyses

the

phenylalanine-pNA amide linkage of the substrate suc-AEPF-pNA. This action
releases free pNA into solution which is then detectable by UVA/IS absorption.
The assay relies on the selectivity of chymotrypsin; chymotrypsin will only cleave
the pNA from the substrate peptide when the E-P bond of the substrate is in the
trans conformation (Figure 1.9).
After the initial burst phase of hydrolysis, the assay is allowed to proceed to
ensure that all remaining substrate in solution is in the cis conformation.
However, there is a small amount of peptide that is converted to the trans
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conformation thermally in solution. This background chemical conversion rate
must be subtracted from the observed isomerization rate to give the Pin 1
isomerization rate. Pin1 is added to the cuvette and as Pin1 isomerizes the
substrate to the trans conformation it is cleaved by Chymotrypsin to release pNA
which is then detectable. As Chymotrypsin is in excess it is assumed that the
release of pNA is dependent on the rate of Pin 1 isomerization.

Inhibitor
C h y m o try p s in

I /

S u c -A E P F -p N A

[ Trans + Cis]

I

pNA

Vis Abs

P in i
S u c -A E P F -p N A

[Cis]

S u c -A E P F -p N A

—

Cis

NH>

C h y m o try p s in

Trans

[Trans]
©
pNA

Figure 1.8 Schematic representation of the Chymotrypsin coupled kinetic assay
developed by Fischer et al. [58]

Figure 1.9 A) peptide substrate suc-AEPF-pNA in the non-cleavable cis conformation
and B) peptide substrate suc-AEPF-pNA in the cleavable trans conformation
22

To determine the effectiveness of the inhibitors, the different inhibitors are
added to the assay cuvette along with the substrate. Curves generated in the
presence of inhibitor are compared to those generated in the absence of an
inhibitor. Though the concentration of substrate varies with each individual trial,
the concentration of Pin1 and the inhibitor remain constant throughout all trials.
The initial amount of substrate in the cis conformation is a major drawback of
the assay. In aqueous solution it was found that 90% of the peptide exists in
trans conformation and thus only 10% of the available peptide could be used for
the determination of rate of isomerization. In 1991 the assay was improved upon
by Kofron et al [62]. Lower temperatures were introduced to reduce proteolytic
cleavage of Pin1 and chymotrypsin as well as to reduce the rate of thermal
conversion. Multiple wavelengths for absorbance measurements were also
added to detect cleavage products at higher concentrations. Finally a novel
solvent system of 50 mM HEPES, 0.1 M NaCI, and 5 mM NaN3 was introduced
which increases the available percentage of peptide in the cis conformation from
10:90 cis.trans to a reported 50:50 cis:trans ratio. The increase of peptide in the
cis conformation increases the confidence these changes to the assay allow for a
more accurate and efficient testing of Pin 1 isomerase activity.

1.13

Thesis Overview
Throughout the literature, long peptide chains dominate as the preferred

type of inhibitor for Pin1. These peptide chains exploit binding in the active site
via the recognition sequence, as well as binding to sites on the periphery of the
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active site. Designing competitive small molecule inhibitors presents a different
challenge as the binding energy must be from a small area directly around the
active site of the target protein. Previous research in this lab has shown that the
substitution of pSer/pThr with (B-phosphorylated glutamic acid increased binding
to Pin 1. This discovery opened doors for a new class of small molecule inhibitors
for Pin 1. Whereas previous inhibitors focused on modifying the proline position of
the recognition sequence and residues removed from the active site. This new
inhibitor focuses on increased binding through the modification of the pSer/pThr
position.
Creating a small peptide inhibitor has advantages over the longer chain and
highly hydrophobic peptides. The advantages include the diminished potential for
non-selective interactions, the smaller inhibitor can potentially be altered with
more ease than the larger chains, smaller molecules have the potential to require
less time to synthesize, and synthesis of smaller molecules has the potential to
be more cost effective. With all these potential advantages there is a higher
chance that therapeutic or research-based use would increase.
The main goal of this research was to use rational design to synthesize novel
inhibitors for Pin1. Using previous findings rational design was used to select
proline

analogues

for

substitution

into

Cbz-/_-Glu(P-phos)-Pro-NH2.

The

substitutions were then assessed for inhibitory potential against Pin1 activity.
Centering the research on the novel p-phosphorylated inhibition strategy, we
sought to increase the binding potential through utilizing the strategy of
substitution at the proline position. It was thought that testing both successful
24

proline mimics in Pin 1 inhibition studies, such as pipecolic acid, and novel proline
substitutions, such as morpholine and methylpiperazine - both chosen in a
rational design fashion, would render a strong, easily synthesized, inhibitor of
Pin 1.
Another goal was to increase the product yield of the Reformatsky addition in
this application as low yields are unfavourable for a multi step synthesis.
This thesis will demonstrate the successful screening of four different Cterminal moieties coupled to p-phosphorylated glutamic acid, all of which are
novel to Pin1 inhibition studies.
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Chapter Two: Results & Discussion

2.1

Synthesis of N, C Protected Serine Aldehyde
Previous work in this lab determined that Cbz-Glu((3-phos)-Pro-NH2 was

active against Pin1 isomerase activity (Kj = 20.0+0.9 pM). It was hypothesized
that the magnitude of inhibition could be increased through substituting the
proline with structural analogs through stronger interaction with the active site of
Pin1. To test this hypothesis four novel dipeptides, which are based on the phydroxyl substituted glutamic acid core molecule, were synthesized.
In 1993 Blaskovich and Lajoie [1] published a novel methodology for the
synthesis of non-proteinaceous, p-substituted a-amino acids. The method utilized
an OBO ester (4-methyl-2, 6, 7-trioxabicyclo[2.2.2]octane ester) as the carboxyl
group protector. The OBO ester provides 1) protection from racemization at the
a-carbon

through

reduction

of a-hydrogen

acidity,

and

2) aids

in the

stereoselective addition to the p-carbon. The p aldehyde of serine is an excellent
intermediate as it allows for the addition to the p-carbon using different strategies
such as the Reformatsky reaction or Grignard reaction.
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Scheme 2.1

The starting material, oxetane tosylate, 1, was prepared on large scale, 20
g,

with

high

yield

(78%)

through

the

addition

of

3-methyl-3-

(hydroxymethyl)oxetane to p-toluenesulfonyl chloride in the presence of pyridine.
Cbz-serine oxetane ester, 2, was then synthesized through the addition of 1 to
Cbz-Ser through the formation of a cesium salt, catalyzed by the presence of the
iodide ion (78%). To complete the protection of the carboxylic acid, the oxetane
ester, 2, was rearranged to the OBO ester using BF3 as a Lewis acid catalyst
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(81%). The (3-hydroxyl was converted to a (3-aldehyde under Swern oxidation
conditions (crude yield of 91%). Purification of the aldehyde, 4, through
chromatography could potentially lead to racemization of the a-carbon through
enolate formation [1]. Thus, the aldehyde was not purified before further reaction.
Fortunately, purification is not a great concern for several reasons: 1) the yield of
a Swern oxidation has been shown to be high [2, 3]; and 2) any alcohol
remaining will not be reactive towards nucleophiles and will be removed in
subsequent purification.

2.2

Reformatsky Addition
After the synthesis of 4, alkylation of the aldehyde was carried out using t-

butyl bromoacetate (tbba) under Reformatsky addition conditions to synthesize
Cbz-Glu(t-Bu)((3-OH)-OBO, 5. The Reformatsky is much like the Grignard
reaction but uses Zn metal in place of Mg to add an acetate group to a carbonyl.
Previous reports presented a yield of 27%; however, the reaction yielded enough
material to continue with the synthesis to the final product. In that instance only
one inhibitor was synthesized using the Reformatsky addition and the low yield
was not investigated. For our purposes ca. 30% yield is a waste of starting
materials and not synthetically favourable. Initial attempts using the prescribed
method yielded 33%, which is still too low for a multi-step synthetic process.
Potential problems could be one, or a combination, of: water contamination; low
yield of the Swern oxidation; incomplete consumption of the reactants; improper
ratios of reactants; and zinc purity.
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Water contamination would cause a “quenching” of the reaction, and thus
could result in low yields. As one of the simplest and most logical problems to
address, fresh reagents were dried using molecular sieves in septum bottles and
handled under argon to ensure that moisture in the air was not contaminating the
reactants. A source of water could also have come from the aldehyde product.
Cbz-Ser(ald)-OBO, 4, was reconstituted in freshly distilled CH2 CI2 and dried over
M gS04 before the solvent was removed in vacuo and then placed under high
vacuum. The apparatus for the reaction was improved by using a two-neck round
bottom flask (RBF) and introducing a stopcock to the second neck under argon
flow, to allow addition of reactants without exposing the reaction to atmosphere.
Performing the Reformatsky with carefully dried reagents and new apparatus
yielded no significant change (34%). Water contamination did not seem to be the
problem. However, the use of fresh dry reagents is always recommended. Thus,
the carefully dried reagents and the improved apparatus were used for the
remaining trials.
The purity of Zn was addressed next. Zn metal was cleaned in
concentrated HCI to remove any oxide, washed with 50%, 70% and 99%
EtOH/H20

solutions, rinsed twice with MeOH and dried at 110°C. The

Reformatsky reaction with purified Zn metal yielded no change (31%).

Purified

Zn was used for the remainder of all subsequent reactions.
The Swern oxidation has been shown to be very effective and result in a
high yield in different applications [2, 3]. However, having an ineffective oxidation
process would lead to low yields in the Reformatsky addition. To determine if the
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aldehyde was the cause of the low yield of the Reformatsky reaction the efficacy
of the oxidation process had to be ascertained. Using TLC as an indicator to
determine completion was not very effective as the aldehyde tended to streak on
the plate. High resolution mass spectrometry also indicated that the product CbzL-Ser(ald)-OBO was synthesized; however, it does not rule out low yield as mass
spectrometry is not quantitative. Fortunately, with 1H NMR one can directly
compare the spectra of Cbz-/_-Ser-OBO, 3, and Cbz-Z_-Ser(ald)-OBO, 4. It is
evident in the Cbz-Z_-Ser(ald)-OBO that the oxidation had been successful
through the gain of a signal peak at 9.69 ppm, which is indicative of an aldehyde.
Complementing the gain of an aldehyde peak would be the loss of the hydroxyl
and the (3-hydrogens signal as well. Both the loss of the hydroxyl peak at 2.51
ppm as well as the loss of the peak at 2.55 ppm which represented the pair of phydrogens can be clearly seen. Please refer to Figures 2.1 and 2.2 for 1H NMR
spectra of Cbz-Z_-Ser-OBO, 3, and Cbz-L-Ser(ald)-OBO, 4, respectively.
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Figure 2.1 400 MHz 1H NMR, CDCI3 , of Cbz-/_-Ser-OBO, 3.
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Figure 2.2 400 MHz 1H NMR, CDCI3, of Cbz-/.-Ser(ald)-OBO, 4.

If the reaction had been of low yield the 1H NMR spectrum of Cbz-LSer(ald)-OBO would contain peaks belonging to both Cbz-/_-Ser(ald)-OBO

as

well as Cbz-/_-Ser-OBO. As the evidence supports that the oxidation was
successful it was thought that the methodology of the Reformatsky addition was
faulty. A survey of the literature revealed that different methods (including
different reagents) were used to achieve Reformatsky additions with higher yields
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[4-7], Many of these reactions were performed over longer periods of time than
what this lab was performing. Some were at room temperature or at reflux.
Without changing the reagents in the synthetic process which was already
developed, attempts were made to increase the yield by changing the addition
order of the reactants as well as changing the length of different reaction stages.
These changes are summarized in Table 2.1.
As Table 2.1 demonstrates many of the changes in methodology show
little to no change in yield, and in some cases lowered yields. However, in trial 27
the quantities of all the reactants were doubled, except for the aldehyde, 4, to 10
equ and the reaction was carried out. This reaction yielded 64% of expected
product upon purification and crystallization. However, it was unclear if the
increase in yield was due to the change in the reagent quantities or the change in
workup extractions that were required. Upon quenching the reaction and during
separation in the workup, it was noticed that there was a significant increase in
the volume of the emulsion layer between the aqueous and ethereal phases.
This layer of insoluble material was not unexpected, as it was present in all
previous workups. However, the increased amount of material proved to be a
challenge in easily separating the layers. As a result more extraction steps with
CH2CI2 were required to properly separate the two layers. With the increased
volume of insoluble matter it was noticeable that during each subsequent
extraction step the emulsion became whiter and less ‘fluffy’. This change was not
immediately apparent in the smaller quantities.
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Trials

Initial reactants
(equ)

Conditions

Additional
reactants (equ)

Reaction
Duration
(Reflux :
cool down)

1-3

Zn (5 equ), Iodine
(cat)

reflux for 10
mins

tbba (5 equ),
Aldehyde (1 equ)

20:30

28-30

4-6

Zn (5 equ), Iodine
(cat)

reflux for 10
mins

tbba (5 equ),
Aldehyde (1 equ)

40:30

19-25

7-10

Zn (5 equ), Iodine
(cat)

reflux for 10
mins

tbba (5 equ),
Aldehyde (1 equ)

60:40

21-26

.........................................

Yield
(%)

...................................

11

Zn (5 equ), Iodine
(cat), tbba (5 equ)

reflux for 10
mins

Aldehyde (1 equ)

20:30

27

12-15

Zn (5 equ), Iodine
(cat), tbba (5 equ)

reflux for 20
mins

Aldehyde (1 equ)

40:30

29-32

16,17

Zn (5 equ), Iodine
(cat), tbba (5 equ)

reflux for 20
mins

Aldehyde (1 equ)

60:30

22-36

18,19

Zn (5 equ), Iodine
(cat), tbba (5 equ)

reflux for 20
mins

Aldehyde (1 equ)

60:60

27-31

20

Zn (5 equ), Iodine
(cat), Aldehyde (1
equ)

reflux for 10
mins

tbba (5 equ)

20:30

14

Aldehyde (1 equ)

20:30

31-32

Aldehyde (1 equ)

40:30

30-35

21-24

Zn (5 equ), Iodine
(cat), tbba (5 equ)

25,26

Zn (6 equ), Iodine
(cat), tbba (6 equ)

Tab e 2.1 Continued on

heated Zn
and Iodine to
reflux then
added tbba
and refluxed
for 15 mins
heated Zn
and Iodine to
reflux then
added tbba
and refluxed
for 15 mins
next page
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27*

28*

29*

Zn (10 equ),
Iodine (cat), tbba
(10 equ)
Zn (5 equ), Iodine
(cat)

Zn (5 equ), Iodine
(cat), tbba (5 equ)

heated Zn
and Iodine to
reflux then
added tbba
and refluxed
for 25 mins

Aldehyde (1 equ)

40:60

64

reflux for 10
mins

Aldehyde (1 equ)
tbba (5 equ)

20:30

58

heated Zn
and Iodine to
reflux then
added tbba
and refluxed
for 25 mins

Aldehyde (1 equ)

20:30

56-67

Table 2.1 Summary of methods attempted. The * denotes trials which were
performed with additional washing steps.

To verify, the reaction was performed using the original five equivalents of
reactants but the workup was altered to include extra extraction steps using
CH2CI2 (trial 28). Again, it was noticed that upon each wash the emulsion
became whiter and less expanded. Part-way through the separation, the
precipitate was collected from the separatory funnel, rinsed with CH2CI2 and the
fraction was spotted on TLC plate and verified by MS. It was found that product,
Cbz-Glu(t-butyl)(p-OH)-OBO, 5, was indeed still present in the insoluble/emulsion
layer. Changing the workup to include more extractions with CH2 CI2 yielded a
maximum 68% product upon purification and crystallization.
It was found that the method used for trials 21-24 was the simplest to
perform and the easiest to control. Separating the additions of the reactants, tbutyl bromoacetate and the aldehyde, lead to less unreacted Zn metal remaining
in the reaction vessel after completion of the reaction. This change also allowed
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for quicker additions of the reactants to the reaction vessel minimizing exposure
to atmosphere.
The stereochemical selectivity for this particular example can be directly
explained using Cram’s model, the Felkin-Anh model as well as 1,2 chelation
control. Figure 2.3 demonstrates the Cram conformation (Figure 2.3 - A), the
most probable conformation using the Felkin-Anh model (Figure 2.3 - B), and
possible conformations using a 1,2 chelation control mechanism (Figure 2.3 - C
and D). The use of the highly coordinating Zn metal, the configuration of the
preexisting stereocenter of the a-carbon, the steric bulk of the OBO ester, and
the existence of a free electron pair on the amide nitrogen all provide excellent
conditions for 1,2 chelation control. Both possible configurations of 1,2 chelation
control render the same stereocenter in the product (Figure 2.3 - E). In addition,
the Felkin-Anh conformation model is also one of the configurations for 1,2
chelation control.
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NHR

Figure 2.3 Newman projections showing addition to Cbz-Ser(ald)-OBO using A) Cram’s
rule, B) most probable addition using the Felkin-Anh model, C/D) possible conformations
of addition using a 1,2 chelation control mechanism E) Newman projection of the major
product formed, 5. Where R is the Cbz protecting group.

2.3

Synthesis of Cbz-Glu(t-butyl)(P-OH)-OH
Selective removal of the OBO ester from 5 was carried out by hydrolyzing

the OBO ester to the 2-methyl-2-hydroxymethyl-1,3-propanediol (MPHD) ester
(not separated) and then selectively removing the MHPD ester over the t-butyl
ester using hydroxide mediated cleavage. Scheme 2.2 demonstrates this
process.
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Scheme 2.2

t-Bu

/
1) LiOH
2)

►
0 1M HCI

Purification of the free acid was found to be extremely difficult using
previously reported methods (unpublished). It was found that purification using
acetone as the eluent for chromatography was extremely difficult and recovery of
product was extremely low. Using EtOAc as the eluent in a silica gel column was
sufficient to separate the product from unwanted materials before crystallization
(78-96%).
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2.4

Selection of Pin1 Inhibitor Analogues
Several proline analogues were chosen to be tested for inhibition activity.

The most obvious candidate for substitution was pipecolic acid. Pipecolic acid is
chemically similar to proline except that it has a six member ring opposed to
proline’s five member ring. Pipecolic acid has been shown in a variety of
examples as an effective proline substitution in Pin 1 inhibition studies [8-12].
Other structures such as morpholine, methylpiperazine, cyclohexylamine,
and aniline were also selected to act as proline analogues. All of these structures
are novel to prolylisomerase inhibition studies. As six member rings these
structures could possibly share the same properties as proline or pipecolic acid,
as well as introduce different electronic interactions through any heteroatoms
present in the ring structures. Cyclohexylamine and aniline are not heterocycles
and have the amide nitrogen removed from the ring structure. This change could
help assess if the Pin1 recognition sequence will allow for better binding of ring
structures not bound to the amide nitrogen directly.
The dipeptide Pip-NAL was also chosen for substitution, due to the high
degree of success Zhang et al [8] had in developing peptide chain inhibitors
crystals. The Pip-NAL core resolved in crystallographic data showed that the
naphthyl side chain interacted with an accessory hydrophobic binding pocket
adjacent to the proline binding pocket in the Pin 1 active site. The choice to use
this core was to demonstrate the effectiveness of the naphthylalanine binding
and showcase the novel p-substituted inhibitor design. Figure 2.4 demonstrates
the different C-terminal structures
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2.5

Synthesis of Pini Inhibitors

2.5.1

Solid Phase Preparation
Both pipecolic acid and NAL have terminal carboxylic acid functionality

which allows for the convenient use of solid phase peptide synthesis.

2.5.1.1 Synthesis of Cbz-Glu(P-phos)-Pip-NH2
N-protected pipecolic acid was coupled to the PAL solid support resin.
Fmoc was removed from the pipecolic acid N-terminal and Cbz-Glu(t-butyl)(pOH)-OH was coupled to the pipecolic acid. Both coupling steps utilized classical
Fmoc chemistry reagents to couple the free N-terminal to the free C-terminal.
The free hydroxyl was subsequently phosphorylated and oxidized

using

phosphoramidite class reagents. The dipeptide was cleaved from the resin and
purified using HPLC yielding 5.8 mg of Cbz-Glu(p-phos)-Pip-NH2, 17.

2.5.1.2 Attempted Synthesis of Cbz-Glu(P-phos)-Pip-NAL-NH2
Unfortunately the tripeptide,

Cbz-Glu(P-phos)-Pip-NAL-NH2, was

not

successfully synthesized. Using the same methods as synthesis of Cbz-Glu(pphos)-Pip-NH2, N-protected NAL was coupled to the PAL solid support resin.
Fmoc was then removed from the NAL N-terminal and N-protected pipecolic acid
was coupled to the NAL N-terminal. Fmoc was removed from pipecolic acid and
Cbz-Glu(t-butyl)(P-OH)-OH was coupled to the growing chain. The free hydroxyl
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was subsequently phosphorylated and oxidized using phosphoramidite class
reagents and H20 2 (mefa-chloroperoxybenzoic acid (mCPBA) was initially used
as an oxidizer. However, upon resin cleavage the process did not yield any
product. The product was then cleaved from the resin, but the first attempt at
synthesis failed to yield any detectable product. At each coupling step a
verification of addition is completed by taking a small sample of the resin from the
reaction vessel and performing a “mini-cleavage” of that resin. The products of
the mini-cleavage are checked with mass spectrometry to detect the change in
the peptide mass. The evidence suggested a loss of product occurred in the final
steps of phosphorylation and oxidation. It was assumed that human error was the
cause of the loss, most likely through an error in addition of the oxidizing agent
mCPBA. The addition of too much oxidizer could cause premature cleavage off
of the resin leading to a loss of product in the washing of the resin. Proceeding
with the second attempt mCPBA was substituted with H20 2, which had proved
successful for the synthesis of both Cbz-/_-Glu((3-phos)-Pip-NH2, 17, and Cbz-/_Glu((3-phos)-Pro-NH2. After several unsuccessful attempts, it was surmised that
during the oxidation of the phosphite ether or during the cleavage from the resin,
a side reaction was causing a decomposition of the product as there was no
detectable product or intermediate in any wash waste or final cleavage.

2.5.2 Liquid Phase Preparation
Morpholine, methylpiperazine, cyclohexylamine, and aniline do not allow
for the use of SPPS because there is no carboxylic acid functionality, or more
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specifically, any other linkable and cleavable functionalities available for a solid
phase synthesis resin. Thus, SPPS is not an option and liquid phase coupling
must be used. Peptide coupling was completed by using 1 equ of Cbz-Z_-Glu(tbutyl)(P-OH)-OH, 1 equ HBTU, 1 equ DIPEA and 1.2 equ of a selected proline
analogue. After coupling, the coupling reagents were removed using a very short
silica column. The eluent was checked for coupled product, much like the mini
cleavage

process

in

SPPS,

and

phosphorylation

was

completed

using

phosphoramidite class reagents. The protecting groups were then removed using
TFA and products were purified using reverse phase HPLC. This process was
done in a fashion similar to solid phase synthesis; intermediate products were
checked by MS but were not collected until the end product (please see Scheme
2.3).
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Scheme 2.3

t-Bu

t-Bu

Yr

1) dibenzyl-N.N-diisopropylphosphoramidite
2) tetrazole
3) H20 2

7, R = Morpholine
8, R = Cyclohexylamine
9, R = N-methylpiperazine

/

98%TFA, 1% TIPS, 1%H20

11, R = Morpholine
12, R = Cyclohexylamine
R = N-methylpiperazine

14, R = Morpholine = 66%
15, R = Cyclohexylamine = 59%
16, R = N-methylpiperazine = 63%

13,

The aromatic ring aniline failed to couple with success, even after 72
hours of continuous reaction. Checking the reaction status by MS indicated that
the starting products were still present in the solution. The reason for the
incomplete reaction can be explained by the aromaticity of the aniline ring
diminishing the nucleophilicity of the amine. The delocalization of the charge
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allows for several resonance structures which have a full positive charge on the
nitrogen, preventing addition to a carboxylic acid (see Figure 2.4).
The distribution of charge around the aromatic ring can be reduced
through the substitution of hydrogen with electron rich groups at the ortho and/or
para positions of aniline. For example, the use of 2-methoxyaniline, as a proline
analogue could prove effective in coupling to Cbz-/_-Glu(t-butyl)(p-OFI)-OH. The
methoxy group at the ortho position would increase the nucleophilicity of the
nitrogen through electrostatic repulsion of electron density at the ortho position.

Figure 2.4 Visualization of electron delocalization in aniline.

Any alternate pursuits to couple aniline to Cbz-/_-Glu(t-butyl)((3-OFI)-OFI
were not made. Also, as the idea to utilize substituted aniline, regrettably, was
generated at the time of writing, no attempts were made to couple Cbz-/_-Glu(tbutyl)(p-OH)-OH to any aniline analogue.
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2.6

Pin1 Inhibitor Activity
To test the

inhibition

potential

of the synthesized

molecules

the

chymotrypsin coupled photometric assay developed by Fischer et al. [13] and
improved upon by Kofron et al. [14] was used.
The photospectrometer was equilibrated at 0°C. Pin1 substrate, sucAEPF-pNA, was then added to the cuvette. After obtaining a baseline reading,
chymotrypsin was then quickly added to the cuvette. As the substrate is a
mixture of both the cis and trans conformations in solution, any substrate in the
trans conformation was cleaved leaving only peptide in the cis form. During the
assay there was a small percentage of substrate which was converted to the
trans conformation thermally and cleaved by chymotrypsin. This is called the
background chemical conversion rate. This can be calculated by measuring the
change in absorbance over time after the initial burst of chymotrypsin cleavage
and before the addition of Pin1. The background chemical conversion rate needs
to be subtracted from the rate of Pin1 isomerization observed.
Pin 1 was quickly added to the cuvette and the reaction was allowed to go
to completion. The slope of the initial part of the curve was used to calculate the
rate of Pin1 isomerization. (Please see Figure 2.5 for a visual representation of
the tangents used to determine the rate of isomerization and the background
chemical conversion rate.) Tangent slopes were determined by visual detection
of the most linear portion of the curve and linear regression was used to ensure
quality of the fit.
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To determine the rate of isomerization the concentration of peptide in the
cis conformation at the time of addition of Pin1 must be known. Because the
concentration of free pNA in solution is dependent on the concentration of
peptide which is cleaved, the concentrations of total peptide as well as the
concentration of peptide in the cis conformation can be determined using Beer’s
law. The concentration of peptide in the cis conformation can be calculated by
using the difference between the absorbance of just prior to the addition of Pin1
and the absorbance upon completion of the assay. To ensure that pNA cleavage
is not the rate limiting step of the assay chymotrypsin is added in excess.
Once the rate of background chemical conversion and the initial rate of
isomerization were calculated the data was plotted on a Michaelis-Menten plot.
Constants are calculated through inversion of the plot to create a LineweaverBurk plot.
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M ins

Figure 2.5 Sample raw data of Chymotrypsin coupled Pin 1 enzym atic assays. A)
R epresentation of assay w ithout inhibitor present. B) Assay in presence of Cbz-/_-Glu(ßphos)-m ethylpiperazine. i represents tim e point where Chymotrypsin is added, ii
represents tim e point where Pin 1 is added, iii represents the tangent line of the
background chem ical conversion rate, and iv represents the tangent line of the initial rate
of Pin1 isom erization.

Substrate was added in increasing quantity to the cuvette to increase the
concentration of available substrate in cis conformation. The amount of peptide in
the cis conformation can never be duplicated exactly throughout runs as the
concentration of cis peptide depends on many factors, such as,

1

) the thermal

conversion rate, 2) time between the addition of substrate and Pin1, and 3) the
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amount of peptide in the cis conformation of the stock solution. For example,
Figure 2.5 A and B are both examples of actual fluorescent data collected with
the initial addition of the same concentration of total substrate. A) Represents
data collected with the concentration of cis peptide determined to be 452 pM in
the absence of an inhibitor and B) represents data collected with cis peptide at
395 pM in the presence of Cbz-/_-Glu(p-phos)-methylpiperazine. The slope of the
tangent lines ii and iv indicate the rate of background chemical conversion rate
(iii) and the rate of initial isomerization of Pin1 (iv).
The results of the chymotrypsin coupled inhibition assays are presented in
Table 2.2, along with a Michaelis-Menten plot of the different active inhibitors
(Figure 2.6).
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Name

Structure
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Table 2.2 Summary of Pini inhibition assays.
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,

OH

No inhibition

Michaelis-Menten Plot of Pini Chymotrypsin
Coupled Kinetic Assay Results

■ No Inhibitor
♦ Z-E(beta-phos)-Proline-NH2
▲Z-E(beta-phos)-Pipecolamide-NH2
• Z-E(beta-phos)-Methylpiperazine

Figure 2.6 Pin 1 inhibition Michaelis-Menten plot of synthesized inhibitors which
demonstrated inhibition activity (n= 1 ).

In previous work it was observed that Cbz-Glu((3 -phos)-Pro-NH2 exhibited
a K, = 20.0 + 0.9 pM, here a Kj = 54.1+1.8 pM is determined. The difference in
the value is most likely due to the use of different Pin1 stocks and isoforms. The
chymotrypsin coupled kinetic assay was performed using the same procedure
aside from the use of full length Pin1. In the previous study only the catalytic
PPIase domain of Pin1 was used for the assay. Because the VWV domain also
binds to proline containing ligands, the full length enzyme would bind more
inhibitor as well as substrate than just the single domain. These differences can
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help account for the difference in Kj between the previously reported value and
the value reported here for Cbz-/_-Glu((3-phos)-Pro-NH2.
The spacious and positively charged phosphate binding cavity in Pin1
could accommodate movement of the phosphate during

Pin1

catalyzed

isomerization of the Pro-pSer/pThr bond [8 ]. If that is indeed true the modified
serine containing a negatively charged acetyl group could help to inhibit the
action in two ways:

1

) by filling up a cavity adjacent to the phosphate moiety

making any “rolling” difficult; and 2 ) by possibly creating a salt bridge or hydrogen
bond with Arg 6 8 , causing binding to Pin1 to become more energetically
favourable. The substitution of proline with analogues should not directly affect
the binding of the phosphate or the postulated interaction between Pin1 and the
negatively charged carboxylic acid.
Analysis of the proline binding pocket of Pin 1 structure published by
Zhang et al. [8 ] (Figure 2.7), shows that there exists more room in the binding
pocket opposite of the hydrophobic residues, towards His59 and His157. The
“greasy” binding pocket formed by Leu122, Met130, and Phe134 allows for
stronger hydrophobic interaction between the inhibitor and the enzyme.
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Figure 2.7 NMR structure of the binding pocket of Pin1. Bound to Pin 1 is the
peptide Ac-Phe-D-Thr(P0 3 )-Pip-NAL-Gln-NH2 (Thr(P0 3 )-Pip-NAL-Gln shown)
adapted from Zheng et al. [8 ].

Substituting proline for pipecolic acid increases the available surface area
of the inhibitor and does not change the chemical properties substantially. The
larger group could bind with higher affinity through more interaction with the
enzyme. This substitution yields only a moderate increase in inhibition over Glu(p-phos)-Pro-NH2.
Increased inhibition qualities of Cbz-/_-Glu(P-phos)-methylpiperazine can
be explained by: the increase in the available surface area for binding; the
heterocyclic ring potentially allowing for hydrogen bonding between His157
and/or His59 and; the methyl group on the amine nitrogen could potentially
protrude into the gap, towards Phe134, increasing interaction between the
inhibitor and Pin 1.
Both Cbz-Glu(p-phos)-morpholine and Cbz-Glu(p-phos)-cyclohexylamine
do not show any inhibitory characteristics. Cbz-Glu(p-phos)-cyclohexylamine
may not exhibit inhibition qualities due to the extra bond length between the ring
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structure and the amide link as the nitrogen is not part of the cyclic structure as it
is in proline. This added length may cause too much of an unfavourable
difference in the structure to be recognized by the selective Pin 1 recognition
sequence, causing little to no binding of the molecule to Pin1. What is interesting
is that Cbz-Glu((3-phos)-morpholine also showed no inhibition for PPIase activity.
It was thought that the inclusion of morpholine would 1) be favourable for
solubility in vivo, as well as

2

) increase binding through hydrogen bonding

potential with the dual histidines in the Pin1 binding pocket. If Cbz-Glu(p-phos)morpholine is compared with Cbz-Glu((3-phos)-methylpiperazine it can be noticed
that there is a high degree of similarity between the two structures. It is possible
that the cyclic ether is not hydrophobic enough to cause sufficient binding to the
greasy binding pocket, but perhaps the methyl group on Cbz-Glu(p-phos)methylpiperazine increases the hydrophobicity of the heterocycle enough to
allowing for binding.

Cbz-Glu(p-phos)-Pro-NH2,

Cbz-Glu(p-phos)-Pip-NH 2

and

Cbz-Glu(p-

phos)-methylpiperazine all differ from previously published inhibitors in that no
inhibitors have utilized the p-carbon of Ser/Thr in the recognition sequence to
increase binding potential. Either p-phosphorylated glutamic acid or the dipeptide
Glu(p-phos)-Pip could be used in conjunction with other peptide based designs
such as those explored by Zhang et al. [8 ], Guo et al. [11], Liu et al. [12], and
Janowski et al. [15], Duncan et al. [16] very recently published a paper exploring
the use of non-phosphorylated cyclic peptides as Pin1 inhibitors. It would be of
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interest to test a substitution of Glu((3-phos)-Pip in the cyclic peptide CRYPEVEIC
at the Y-P position to determine if the peptide exhibited stronger inhibition.
Although substituting p-phosphorylated glutamic acid would defeat the purpose
of having a non-phosphorylated peptide, it would be interesting to see if there is
any change in inhibitory potential if Glu((3-phos)-Pip is substituted into the cyclic
peptide.
Unfortunately, due to the lack of a linkable group on methylpiperazine, the
core of Cbz-Glu(p-phos)-methylpiperazine is not compatible with other peptide
designs or strategies for Pin1 inhibition. However, if 4-Methyl-piperazine-2carboxylic acid were to be used then it would be possible to link into a peptide
chain. 4-Methyl-piperazine-2-carboxylic acid would contain the same functional
groups thought to increase inhibition but would give the additional functionality of
allowing a second peptide bond.
As an example, to compare Cbz-Glu((3-phos)-Pip-NH2 and Cbz-Glu((3phos)-methylpiperazine to compounds such as PiJ and PiB [17] (Figure 2.8) it
can be easily seen that PiJ and PiB are highly hydrophobic compounds whereas
Cbz-Glu((3-phos)-Pip-NH2 and Cbz-Glu((3-phos)-methylpiperazine are not. The
interaction of Pib and PiJ with Pin 1 have been demonstrated using NMR [17],
however, interactions with other enzymes are highly likely due to non-specific
binding to hydrophobic surfaces on many different proteins. Also unlike PiB and
PiJ,

Cbz-Glu(|3-phos)-Pip-NH2

and

Cbz-Glu(p-phos)-methylpiperazine

are

designed to be specific to the Pin1 recognition sequence. Hopefully, Cbz-Glu(P-
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phos)-Pip-NH 2 and Cbz-Glu((3-phos)-methylpiperazine would have reduced non
specific interactions as they do not contain large hydrophobic groups.

Figure 2.8 Structural representations of PiB and PiJ

One of the goals of this research was to test several proline analogues for
stronger inhibition than Cbz-L-Glu(p-phos)-Pro-NH 2 (Kj = 54.1+1.8 pM), in the
hopes of developing a sub pM range inhibitor. Unfortunately, we were unable to
obtain a sub pM range inhibitor. However, Cbz-/_-Glu((3-phos)-Pip-NH2 (Kj =
45.4+1.1 pM) and Cbz-/_-Glu(p-phos)-Methylpiperazine (Kj = 22.7+1.4 pM) both
demonstrated a stronger inhibition of Pin 1 than Cbz-Z_-Glu(p-phos)-Pro-NH2.
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Chapter Three: Experimental Section

3.1

Instrum entation
NMR spectra were collected using acetone-d6 (referenced to 2.05 ppm for

1H NMR, 29.9 ppm for 13C NMR), CDCI3 (referenced to TMS at 0.00 ppm for 1H
NMR, to CDCI3 at 77.23 ppm for 13C NMR), or D20

(referenced to 3-

(trimethylsilyl)propionic-2 ,2 ,3 ,3 -d 4 acid at 0.00 ppm for both 1H NMR and 13C
NMR) on a Varian Mercury 400 MHz spectrometer. For any NMR samples using
CDCI3 which contained an OBO ester, the CDCI3 was pre-filtered through basic
alumina to remove any traces of acid to retain product integrity during
measurement.
Melting points were determined using a Mel-Temp melting temperature
apparatus using open capillary tubes. Melting temperatures recorded are
uncalibrated.
Mass spectral (MS) analyses were performed on a Micromass Quattro
Micro ESI-MS instrument. Accurate mass/elemental analysis was carried out
using a Varian QFT-12 FT-ICR.
TLC was carried out on EMD Chemicals Inc. aluminum backed silica gel
60 F2 5 4 , with visualization of spots by UV or a solution of 2% ninhydrin in MeOH
and UV.

Flash chromatography was performed with silica gel 60 (70-230 mesh)

from EMD Chemicals Inc.
Semi-preparative HPLC analyses were performed using a Waters 600E
HPLC system controller with a Waters 600 multisolvent delivery system and
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detection was carried out using a Waters 2487 Dual A absorbance detector. The
column used was Agilent Zorbax 300SB-C18 (250x9.4mm, 5 pm). Analytical
HPLC analyses were performed using Agilent 1100 Series HPLC system with a
Phenomenex Jupiter 5u C18 300A (250x2mm, 5 pm) column coupled with the
Micromass Quattro Micro ESI-MS to positively identify elution peaks.

3.2

Reagents
Triethylamine,

boron

oxalyl

trifluride etherate,

chloride,
pyridine,

triflu roacetic

acid,

dibenzyl

morpholine,

1-N-methylpiperazine,

diisopropylethylamine,
tert-butyl

tetrahydrofuran,

bromoacetate,

N,N-diethylphosphoramidite,

ethyl

acetate,

dimethylsulfoxide,

3-methyl-3-oxetanemethanol

(oxetane),

cyclohexylamine, mefa-chlorobenzoic acid, pipecolic acid were purchased form
Sigma-Aldrich and used without any further purification.
Iodine, dimethylformamide, cesium carbonate, p-toluenesulfonyl chloride
and sodium iodide were purchased from Caledon Labs and dichloromethane was
purchased from J.T. Baker.
PAL amide resin was purchased from Advanced Chemtech; Cbz-serine
and peptide coupling

reagents HOBT and HBTU were purchased from

Novabiochem.
Full Pin 1 enzyme was collected and purified from recombinant E. Coli and
graciously given by the Shilton lab.
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3.3

Chemical Synthesis

3.3.1 Oxetane Tosylate, 1
3-Methyl-3-(toluenesulfonyloxymethyl)oxetane, Oxetane tosylate, 1. 57.2 g (0.3
mol) of p-toluenesulfonyl chloride was dissolved in dry pyridine (250 ml_) under
argon. 3-Methyl-3-(hydroxymethyl)oxetane (20.4 g, 0.2 mol) was added slowly,
and the solution was stirred for 1.5 h. The mixture was added slowly to a rapidly
stirring mixture of deionized water (700 ml_) and crushed ice (700 g,) in a 2 L
Erlenmeyer flask and allowed to stir for an additional 0.5 h. The white precipitate
was then vacuum filtered on Whatman filter paper # 1 and washed with cold H2 0.
The product was dried under high vacuum to obtain the white powder of oxetane
tosylate (36.8 g, 78%). Mp 48-50°C (lit 49.5-51°C [1]) 1H NMR (CDCI3, 400 MHz)
5

1.30 (s, 3H), 2.44 (s, 3H), 4.16 (s, 2H), 4.38 (m, 4H), 7.39 (d, 2H), 7.81 (d, 2H).

High resolution

MS calc’d for C i 2 H i 6 0 4SiNa

(M+Na+) 279.06615, found

279.06611 (M+Na+).

3.3.2 Cbz-L-Ser-Oxetane Ester, 2
2-Benzyloxycarbonylamino-3-hydroxypropionic acid 3-methyloxetane-3-ylmethyl
ester, Cbz-L-Ser-Oxetane ester, 2. 1 (11.36 g, 0.047 mol) and Cs2 C 0 3 (9.19 g,
0.028 mol, 0.6 equ) were combined and dissolved in a 500 mL round bottomed
flask (RBF) using 100 mL deionized H2 0 . The water was then removed in vacuo,
and the resulting oil was lyophilized for 12 h yielding white foam. The foam was
then taken up in DMF (200 mL), oxetane tosylate, 1 (12.65 g, 0.049 mol) and Nal
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(1.41 g, 9.8 mmol, 0.2 equ) were added and allowed to stir under Ar for 48 h.
The DMF was then removed in vacuo, and the resulting solid was dissolved
using alternating aliquots of EtOAc (600 ml_ total) and H20 (200 mL total). The
organic layer was separated and extracted with 10% NaHC0 3 (2x 100 mL) and
saturated NaCI (1 * 100 mL), and then dried over M gS04. The solvent was
removed under reduced pressure to yield a yellow oil which was recrystallized
from Et20 to yield colorless rod-like crystals in 78% yield (11.9 g). mp 62-64°C (lit
[2] 58-60°C); [a]20D = -8.2 (c = 0.875, EtOAc) (lit [2]-8.3, c = 1.0, EtOAc); TLC
(2:1, EtOAc:Hexane), R, = 0.42; 1H NMR (CDCI3, 400 MHz) 61.26 (br s, 3H),
2.88 (t, 1H), 3.88-3.95 (br m, 1H), 4.07-4.17 (br m, 2H), 4.42-4.58 (br m,

6

H),

5.14 (s, 2H), 5.74 (d, 1H), 7.28-7.40 (br m, 5H). High resolution MS calc’d for
C 1 6 H2 iN 0 6Na (M+Na+) 346.12611, found 346.12632 (M+Na+).

3.3.3 Cbz-L-Ser-OBO Ester, 3
[2-Hydroxy-1 -(4-methyl-2,6,7-trioxa-bicyclo[2.2.2]oct-1 -yl)-ethyl]-carbamic
benzyl ester, Cbz-/_-Ser-OBO ester, 3.

acid

Cbz-/_-Ser-Oxetane ester, 2 (12.14 g,

36.6 mmol) was dissolved in dry CH2 CI2 (450 mL) and cooled to 0 °C under Ar.
BF3 Et20 (0.23 mL, 1.83 mmol) was diluted in CH 2 CI2 (5.0 mL) and added to the
reaction flask. The reaction was allowed to warm to room temperature and was
checked by TLC.

After

6

h, Et3N (1.28 mL, 9.15 mmol) was added and the

reaction was stirred for an additional 30 min before being concentrated in vacuo
to a thick clear oil.

The crude product was re-dissolved in EtOAc (400 mL),

washed with 3% NH4CI (2 x 250 mL), 10% NaHC0 3 (1 x 250 mL) and saturated
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NaCI

(1

x 250 mL), dried (MgS04), and evaporated to dryness.

The reaction

yielded faintly yellow thick oil. The oil was crystallized from EtOAc/Hexane to
give shiny rod-like crystals in 80.5% (9.52 g) yield. [a]20D = -24.3 (c = 1.025,
EtOAc) (lit [1] -24.8, c = 1.00, EtOAc); mp 105-107°C (lit [1] 103.5-105°C); TLC
(2:1, EtOAc:Hexane), Rf = 0.42; 1H NMR (CDCI3, 400 MHz)
(t, 1H), 3.61 (m, 2H), 3.85-3.95 (m,

8

6

0.82 (s, 3H), 2.51

H), 5.12 (m, 2H), 5.30 (d, 1H), 7.25-7.39 (m,

5H). High resolution MS calc’d for C 1 6 H2 iN 0 6Na (M+Na+) 346.12611, found
346.12608 (M+Na+).

3.3.4 Cbz-L-Ser(ald)-OBO Ester, 4
[1 -(4-Methyl-2,6,7-trioxa-bicyclo[2.2.2]oct-1 -yl)-2-oxo-ethyl]-carbamic acid benzyl
ester, Cbz-/_-Ser(ald)-OBO Ester, 4. Cbz-L-Ser-OBO Ester, 3, (9.1 g, 28 mmol)
was dissolved in freshly distilled CH2 CI2 (80 mL) under Ar and cooled to -78 °C in
flask 1 (100 mL RBF). 22.5 mL of oxalyl chloride (2.0 M in DCM, 45 mmol, 1.60
equ) was added to dry CH2 CI2 (100 mL) in a separate 250 mL round-bottom flask
(flask 2) under Ar and cooled to -78 °C. Dry DMSO (7 mL, 90 mmol, 3.2 equ)
was added to the oxalyl chloride solution (flask

2

), and the mixture was stirred at

-78 °C for 15 min. The solution in flask 1 was transferred slowly by cannula to
flask 2 over a period of 45 min and then rinsed with dry CH 2 CI2 (25 mL). The
resulting cloudy, white mixture was stirred for 1.5 h at -78 °C. DIPEA (24.27 mL,
0.14 mol, 5 equ) was added and the solution stirred for 30 min at -78 °C and 10
min at 0 °C. Ice-cold CH2 CI2 (250 mL) was added, and the solution was washed
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with ice-cold 3% NH4CI (3 * 250 mL) aqueous 10% NaHC0 3 (1 x 250 mL) and
saturated NaCI (1 * 250 mL), dried (MgS04), and evaporated to dryness. The
product was placed on hi-vacuum for 24 hours to remove any solvent remaining
to ensure dryness. The reaction yielded a pale yellow solid in 91.3% (7.92 g)
yield. [a]20D = -78.1 (c = 0.95, EtOAc) (lit [1] -99.3, c = 1.03, EtOAc); TLC (1:1,
EtOAc:Hexane), Rf = 0.8; 1H NMR (CDCI3, 400 MHz)
m,

6

5

0.81 (s, 3H), 3.82-3.98 (br

H), 4.61 (d, 1H), 5.04-5.16 (br m, 2H), 5.36 (d, 1H), 7.24-7.40 (br m, 5H),

9.69 (s, 1H). High resolution MS calc’d for C i 6 H i 9 N 06Na (M+Na+) 344.11046,
found 344.11051 (M+Na+).

3.3.5 Cbz-L-Glu(OtBu)(p-OH)-OBO Ester, 5
4-Benzyloxycarbonylamino-3-hydroxy-4-(4-methyl-2,6,7-trioxa-bicyclo[2.2.2]oct1-yl)-butyric acid tert-butyl ester, 5. Zinc powder (100 mesh, 0.500 g, 7.70 mmol,
5 equ), iodine (2 small crystal), and dry THF (30 mL) were heated to reflux in a
dry 100-mL flask under Ar. Tert-butyl bromoacetate (1.25 mL, 7.70 mmol, 5 equ)
was added quickly to the refluxing solution and rinsed with 5 mL THF. Solution
was allowed to reflux until all Zn had reacted, approx 15 mins. At that point, a
solution of crude Cbz-Z_-Ser(ald)-OBO Ester, 4, (0.500 g, 1.17 mmol, assuming
100% yield of the aldehyde from oxidation) in 15 mL of THF was added.
solution was refluxed for

20

The

min, allowed to cool to room temperature

(approximately 30 mins), and then poured into 150 mL of aqueous 5% NH4 CI.
CH 2 CI2 ( 1 0 0 mL) was added, and the organic layer was separated, washed with
5% NH4CI (1 x 150 mL) and saturated NaCI (1 x 150 mL), dried (MgS04), and
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evaporated to dryness yielding

clear oil.

Purification by flash

column

chromatography (silica gel, 2:1 EtOAc:hexane), and recrystallization gave 0.320
g (6 8 % yield over two steps) of a white solid, mp 48-51 °C (previous unpublished
work 48-51 °C); [a]20D = -6.3 (c = 1.00, EtOAc) (previous unpublished work [a]20D
= -6.2 c = 1.00, EtOAc); TLC (1:1, EtOAc:hexane) Rf = 0.61; 1H NMR (CDCI3,
400 MHz)

6

0.82 (s, 3H), 1.43 (m, 9H), 2.38-2.50 (m, 2H), 3.03 (s, 1H), 3.82-3.96

(m, 7H), 4.62 (m, 1H), 5.12 (m, 1H), 5.35 (d, 1H), 7.23-7.38 (m, 5H); High
resolution MS calc’d for C2 2 H3 1 NO8 (M+H+) 438.21224, found 438.21223 (M+H+).

3.3.6 Cbz-L-Glu(OtBu)(P-OH)-OH, 6
2-Benzyloxycarbonylamino-3-hydroxy-pentanedioic acid 5-tert-butyl ester, Cbz-/_Glu(OtBu)((3-OH)-OH, 6. Cbz-/_-Glu(0tBu)((3-0H)-0B0 Ester, 5 (0.15g, 0.34
mmol) was dissolved in 40 ml_ EtOAc. 4 mL of 5% TFA solution in DCM was
added and the reaction mixture was stirred for 2 h under Ar.

Conversion to

intermediate product 2-Benzyloxycarbonylamino-3-hydroxy-pentanedioic acid 5tert-butyl

ester

1-(3-hydroxy-2-hydroxymethyl-2-methyl-propyl)

ester,

checked by MS [calc’d for C2 2 H3 3 O9 N for 455.50, found 456.26 (MH+)].

was
The

reaction mixture was evaporated to oil, and re-dissolved in 40 mL THF. 40 mL of
LiOH (45mM, 5 equ) was added to the solution, and stirred for 20 h at room
temperature. The solution was acidified with 0.1N HCI to pH4.0, and extracted
with EtOAc (3 x 50 mL). The organic layer was dried (MgS04) and evaporated to
an oil.

Purification by flash column chromatography (silica gel, EtOAc) and

recrystallization (acetone:CH 2 CI2) yielded colorless crystals (78-96%, 0.96 g 68

0.118 g): mp 58-60 °C; [a]20D = +1.1 (c = 0.52, acetone); TLC (acetone) Rf =
0.25; 1H NMR (acetone-d6 /D 2 0 , 400 MHz) 6 , 1.42 (s, 9H), 2.38-2.60 (br m, 2H),
4.38 (b, 1H), 4.63 (b, 1H), 5.01-5.15 (br m, 2H), 7.22-7.42 (br m, 5H); High
resolution MS calc’d for C 1 7 H2 3 N0 7Li (M+Li+) 360.16291, found 360.16325
(M +Li+).

3.3.7 General Liquid Phase Peptide Coupling and Phosphorylation
1 equ of Cbz-/_-Glu(OtBu)(p-OH)-OH is dissolved in CH2 CI2:DMF (1:1, 40
mL) along with 0.1 equ HOBt, 0.95 equ HBTU and 1 equ of DIPEA x under
nitrogen and stirred for 5 min. 1.2 equ of the C-terminal amine was added to the
reaction vessel and stirred for 24 h. Solvent was removed under strong vacuum
to produce a yellow mixture of oil and solid. The mixture was brought up in a
minimum volume of CH2 CI2 and purified by flash column chromatography (silica
gel, CH 2 CI2).Dibenzyl N,N-diethylphosphoramidite (12 equ) is added to a solution
of the Cbz N-protected dipeptide in THF (10 mL) under argon in a 50 mL RBF.
1H-Tetrazole (2.5 equ) is then quickly added to the solution and stirred for 25 min
at room temperature. The solution is cooled in an acetone/dry ice bath and a
solution of 85% mCPBA (12 equ) in CH2 CI2 is slowly added, the solution is
removed from the dry ice bath and allowed to stir for

20

min at room temperature.

10 mL of a 10% Na2 S2 0 5 solution is added to the mixture and the aqueous phase
is separated and discarded. The ethereal phase is washed with 10% Na2 S2 0 5 (1
x 30 mL), 5% NaHC0 3 (2 x 30 mL), 5% citric acid (pH 3.3: 1 x 30 mL) and
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backwashed with 5% NaHC0 3 (30 mL), dried with MgS0 4 and filtered. Solvent
was removed in vacuo to produce an oil. The product was lyophilized to remove
any trace water, and the phosphorylation process was repeated once more. The
product was verified using MS then immediately cleaved.

3.3.8 General Protocol for Cleavage of Protecting Group
50 mL of a 95% TFA/5% H20 solution was added to a 100 mL RBF
containing the protected phospho-dipeptide and stirred for 4 hours. TFA and H20
were removed in vacuo and the resulting product was brought up in 50 mL H20
and 20 mL Et2 0. The ethereal phase was discarded and the aqueous phase
washed with Et20 (2 x 20 mL). The solvent was removed in vacuo to ensure
complete removal of any organic solvent, and lyophilized. The product was
purified using RP FIPLC (solvent A: hl2 0, solvent B: Acetonitrile).

3.3.9 Solid Phase Peptide Synthesis
PAL resin (100 mg, 0.05 mmol) was swelled in CH2 CI2 (20 mL for 10 min),
and rinsed with DMF (2 x 20 mL). For every amino acid coupling cycle, the Fmoc
group was removed using 20% piperidine in DMF (20mL for 2x10 min). After
washing the reaction vessel carefully with DMF (4 x 20 mL), a solution of amino
acid (4 equ), HOBt (3.8 equ), HBTU (0.5 equ), and DIPEA (4 equ) in DMF/DCM
(20 mL) was added to the resin, shaken for 4 h washed, rinsed and repeated.
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3.3.10 Resin Cleavage and Protecting Group Removal
A solution of TFA/H20 (95:5) was used to simultaneously cleave the resinamide bond and remove all protecting groups except the Cbz group. 50 ml_ of
solution was used and stirred for

hours. The solution was filtered to remove

6

resin and the solvent was removed in vacuo. The resulting product was brought
up in 50 ml_ H20 and 30 mL Et20 and the ethereal phase discarded. The
aqueous phase was washed with Et20 (2 x 30 mL). Solvent was removed in
vacuo to ensure complete removal of any organic solvent and lyophilized.
Product was purified using RP HPLC (solvent A: H2 0 , solvent B: Acetonitrile).
The peptides were then checked by high resolution MS analysis.

Compounds 14 through 17 are categorized by the retention time and MS.
Results are summarized in Table 3.1

Name
Cbz-L-Glu(P-phos)-

HPLC RT
(min)
(5-95%
/90min)

Purity
(%>

36.86

95.3

Mass Spectrometry
FTMS Calc’d.obs
(ppm)
447.11631 : 447.11663

morpholine, 14
Cbz-L-Glu(p-phos)-

0.7157 ppm
33.16

89.7

459.15269 : 459.15271

cyclohexylamine, 15
Cbz-/_-Glu(p-phos)-

0.0436 ppm
18.82

96.4

460.14794 : 460.14802

methylpiperazine, 16
Cbz-L-Glu(P-phos)-

0.1739 ppm
26.77

94.8

510.12480 : 510.12483

Pip-NH2, 17

0.0588 ppm

Table 3.1 Summary results of peptides synthesized.
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3.3.11 Chymotrypsin Coupled Kinetic Assay
Assay buffer contained 50 mM HEPES, 0.1 M NaCI, 5 mM NaN 3 and was
brought to pH 7.4 with NaOH (amount used varied to maintain a consistent end
volume of 2 ml_ per assay). Chymotrypsin solution (50 mg/mL in 1 mM HCI, 50
pL per assay) was made fresh in 500 pL quantities and stored at 0°C to ensure
minimal degradation of chymotrypsin. The Pin1 substrate solution was prepared
using dry TFE and contained 25 mM of Suc-AEPF-pNA (kcat/Km = 3410 mM' 1 s'1),
and 0.3M LiCI. Pin1 solution was prepared at 0.125 mg/mL (50 pL per assay; 170
nM final concentration)
The assay buffer and substrate solution were added to a clean cuvette
and equilibrated until 0°C was reached. When used, Pin1 inhibitors were added
directly to the buffer and substrate in the cuvette prior to assay start. Assays
were performed at 0°C to minimize proteolytic degradation of Pin1 and chemical
conversion of cis substrate to trans.
Measurement of absorbance was started and chymotrypsin solution was
added to the cuvette. When absorbance reached a steady state Pin 1 solution
was added quickly and reaction was allowed to go to completion. Measurements
of the Pin1 constants were performed according to Kofron et al. [3] and evaluated
by Microsoft Excel.
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Chapter Four: Conclusion

4.1

Conclusion
Alterations in the expression levels, in either direction, of human Pin1 can

have an effect on the development of cancer and other diseases caused by cell
cycle deregulation, Tau related pathologies, as well as HIV proliferation. The
phosphorylation dependency that Pin1 exhibits makes it an attractive target for
specific anti-cancer and anti-HIV drugs. Unfortunately, reduced Pin 1 activity has
been shown to increase tau related pathologies such as Alzheimer’s disease.
Being able to control the rate of Pin1 activity in neural tissue may be valuable in
studying Alzheimer’s disease.
Slight modifications to the work-up of the Reformatsky addition proved to
increase the yield of the reaction from a reported 27% to

6 8

%.

Substituting the proline in Cbz-/_-Glu(p-phos)-Pro-NH2 with pipecolic acid
improved the inhibition capabilities from 54.1+1.8 pM to 45.4+1.1 pM, as
determined using full length Pin 1 in the chymotrypsin-coupled kinetic assay.
Substituting proline with N-methylpiperazine demonstrated stronger inhibition
qualities with a Kj of 22.7+1.4 pM.
These small inhibitors have advantages over the larger counter parts
developed in other research laboratories. While many other inhibitors to date
exhibit stronger Kj values, much of these have peptide sequences which,
presumably, interact with Pin1 at sites removed from the active site. The smaller,
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site-specific di- or tripeptides, which act solely at the active site of Pin1, may
diminish nonspecific binding in vivo.
In summary, we were able to increase the efficiency of the methods used
to stereospecificly synthesize Cbz-/_-Glu(t-butyl)(p-hydroxy)-OBO, synthesize
novel Pin 1 inhibitor candidates, screen them for activity using a chymotrypsincoupled enzymatic assay, and discover two stronger acting inhibitors over Cbz-LGlu((3-phos)-Pro-NH2. Unfortunately, discovery of a nanomolar inhibitor was not
achieved.

4.2

Future Work
The work in this thesis furthers the research work from previous theses

from this lab. The author suggests that further research be taken to investigate
the crystal or possibly the NMR structure of Pin 1 bound to the small inhibitor
Cbz-/_-Glu(p-phos)-Methylpiperazine, 16, and Cbz-L-Glu(p-phos)-Pip-NH2, 17.
This would provide structural evidence that the negatively charged glutamic acid
does interact with the positively charged Lys63 or Arg6 8 as postulated. The
structural information would also provide details on any contact with the deeper
proline binding pocket in which the dual histidines reside. This information could
lead to structural based designs of better small inhibitors.
Based on the published structure of the pipecolic acid naphthylalanine
containing peptide by Zhang et al. this author strongly suggests further work into
the synthesis of Cbz-Glu(p-phos)-Pip-NAL-NH2, possibly through non-solid
phase synthesis strategies. The author also suggests that further research into
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targeting various kinases and phosphatases, which are known to be active in
cancer proliferation, using the optimized methodology and structure of the Pin1
inhibitors demonstrated in this thesis.
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